Breast cancer resistance protein (BCRP)-mediated glyburide transport: Effect of the C421A/Q141K BCRP single-nucleotide polymorphism

Drug Metabolism and Disposition

Volumn 38, Issue 5, 2010, Pages 740-744

  Pollex, Erika K ^a,b   Anger, Gregory ^b   Hutson, Janine ^a,c   Koren, Gideon ^a,b,c   Piquette Miller, Micheline ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; GLIBENCLAMIDE;

ARTICLE; CELL STRAIN HEK293; CELL TRANSPORT; DRUG TRANSPORT; EXPRESSION VECTOR; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; MEMBRANE TRANSPORT; MUTATION; PLACENTAL TRANSFER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; CELL MEMBRANE; CYTOPLASM; GLYBURIDE; HUMANS; INDOLES; KINETICS; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSFECTION;

EID: 77950944714     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.030791     Document Type: Article

References (22)

1. Bachmeier CJ, Trickler WJ, and Miller DW (2006) Comparison of drug efflux transport kinetics in various blood-brain barrier models. Drug Metab Dispos 34:998-1003.
2. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
3. de Jong FA, Marsh S, Mathijssen RH, King C, Verweij J, Sparreboom A, and McLeod HL (2004) ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 10:5889-5894. (Pubitemid 39180970)
4. Elliott BD, Langer O, Schenker S, and Johnson RF (1991) Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol 165:807-812.
5. Elliott BD, Schenker S, Langer O, Johnson R, and Prihoda T (1994) Comparative placental transport of oral hypoglycemic agents in humans: a model of human placental drug transfer. Am J Obstet Gynecol 171:653-660. (Pubitemid 24312344)
6. Feig DS, Briggs GG, and Koren G (2007) Oral antidiabetic agents in pregnancy and lactation: a paradigm shift? Ann Pharmacother 41:1174-1180.
7. Gabbe SG, Gregory RP, Power ML, Williams SB, and Schulkin J (2004) Management of diabetes mellitus by obstetrician-gynecologists. Obstet Gynecol 103:1229-1234.
8. Gedeon C, Anger G, Piquette-Miller M, and Koren G (2008) Breast cancer resistance protein: mediating the trans-placental transfer of glyburide across the human placenta. Placenta 29:39-43.
9. Gedeon C, Behravan J, Koren G, and Piquette-Miller M (2006) Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta 27:1096-1102. (Pubitemid 44400512)
10. González-Alvarez I, Fernández-Teruel C, Garrigues TM, Casabo VG, Ruiz-García A, and Bermejo M (2005) Kinetic modelling of passive transport and active efflux of a fluoroquinolone across Caco-2 cells using a compartmental approach in NONMEM. Xenobiotica 35:1067-1088.
11. Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, Dean M, and Bates SE (2002) Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ ABCP1). Cancer Biol Ther 1:696-702.
12. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, and Sugimoto Y (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1:611-616.
13. Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, Kobayashi D, Ieiri I, Mine K, Ohtsubo K, and Sugiyama Y (2004) Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res 21:1895-1903. (Pubitemid 39390103)
14. Kraemer J, Klein J, Lubetsky A, and Koren G (2006) Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Am J Obstet Gynecol 195:270-274. (Pubitemid 43927503)
15. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464. (Pubitemid 32695041)
16. Mizuarai S, Aozasa N, and Kotani H (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int J Cancer 109:238-246. (Pubitemid 38240926)
17. Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, and Bates SE (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 56:161-172. (Pubitemid 40884271)
18. Pollex E, Lubetsky A, and Koren G (2008) The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta 29:743-747.
19. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, and McLeod HL (2004) Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 76:38-44. (Pubitemid 38844732)
20. Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD, Nooter K, and Gelderblom H (2005) Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther 4:650-658.
21. Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, and Schuetz EG (2003) Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13:19-28. (Pubitemid 36135683)
22. Zhou L, Naraharisetti SB, Wang H, Unadkat JD, Hebert MF, and Mao Q (2008) The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol Pharmacol 73:949-959.